Insulet Corporation (PODD) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $-0.19 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.22. The company posted revenue of $81.21 million in the period, compared to analysts expectations of $79.25 million. The company’s revenue was up 68.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.21 EPS.
Many Wall Street Analysts have commented on Insulet Corporation. Company shares were Upgraded by The Benchmark Company on Feb 26, 2016 to ” Buy”, Firm has raised the Price Target to $ 40 from a previous price target of $30 .
Insulet Corporation opened for trading at $34.43 and hit $35.07 on the upside on Wednesday, eventually ending the session at $34.7, with a gain of 0.67% or 0.23 points. The heightened volatility saw the trading volume jump to 9,58,991 shares. Company has a market cap of $1,978 M.
In a different news, on Mar 11, 2016, Daniel J Levangie (President, Drug Delivery) sold 12,299 shares at $30.84 per share price. According to the SEC, on Mar 3, 2016, Jessica Hopfield (director) purchased 3,230 shares at $30.91 per share price. On Aug 24, 2015, Bradley A Thomas (EVP Human Resources) purchased 845 shares at $29.41 per share price, according to the Form-4 filing with the securities and exchange commission.
Insulet Corporation is a medical device company engaged in the development manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System) an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica Massachusetts. Features of the OmniPod System include two-part design no tubing and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod a small lightweight disposable insulin infusion device worn beneath clothing; and the PDM a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated hands-free cannula insertion system.